Recent studies have shown a concerning rise in testicular cancer incidence among Hispanic populations. This trend highlights a critical need for increased awareness and early diagnostic efforts. Research to understand this rise is ongoing. Aditya Bagrodia, MD, associate professor of urology and radiation oncology at UC San Diego School of Medicine and urologic oncologist at UC San Diego Health, is available to discuss this topic during Testicular Cancer Awareness Month.
Biography :
Aditya Bagrodia, MD, is a board-certified urologist specializing in detecting, treating, and preventing genitourinary cancer. He is experienced in surgical and nonsurgical treatments for all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He also has expertise in minimally invasive approaches to urologic surgery.
He has focused his clinical and research interests on understanding the molecular attributes of germ cell tumors, that cause testicular cancer, to improve treatments and clinical care.
As an associate professor in the Department of Urology, Bagrodia trains medical students, residents, and fellows at UC San Diego School of Medicine, where he leads the genitourinary disease team. He has focused his clinical and research interests on understanding the molecular attributes of germ cell tumors, that cause testicular cancer, to improve treatments and clinical care. He also has been actively involved in understanding and overcoming societal and epidemiological barriers to optimal care in testicular cancer patients.
Bagrodia has been involved in clinical trials for patients with testicular cancer and has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He has been funded through intramural research grants and competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health. (Newswise/TAB)
